Karen & David Miller; Mike Kahn, Tysabri FDA testimony for MS (Multiple Sclerosis)

In March 2006 the FDA hosted a public hearing via an advisory committee, to gain public input as to the return of Antegren (natilzumab) to the market. Originally approved and heralded as the next generation of MS treatment, offering significantly greater efficacy than other MS treatments, it was withdrawn from the market due to concern about side effects. Due in large part to patient advocacy and these FDA subcommittee testimonies, the committee unananimously recommended to the FDA that natalizumab be returned to the market. Natalizumab was retuned to the market in summer of 2006, and marketed under the name of Tysabri. For many MS patients, Tysabri is a life-giving medicine, dramatically improving their physical and cognitive well-being, and is the safest and most efficacious MS drug available today.

Category:

Science & Technology

Tags:

• MS
• multiple
• sclerosis
• drug
• trial
• FDA
• antegren
• natalizumab
• avonex
• biogen
• idec
• elan
• video
• touch
• NMSS

[pdixon9111]

Thank you to ALL who took a stand on behalf of MS Fighters, and Tysabri. Thank you for making a difference and giving MS Fighters a CHOICE. Thank you, Thank you , Thank you.

[jlccom]

Thank you, Karen and David, for your courage in speaking out. I can only imagine what this cost you!

Love to you both,

Joseph & Michele

[chiromom1]

Thank-you, Thank-you, Thank-you. Love to you both. Sarah